Poseida Therapeutics Valuation

Poseida Therapeutics Investor Information

About 28.0% of the company outstanding shares are owned by corporate insiders. The company has Price/Earnings (P/E) ratio of 214.0. Poseida Therapeutics recorded a loss per share of 0.63. The entity last dividend was issued on the June 23, 1992. The firm had 3:1 split on the April 5, 2005. Based on the key indicators related to Poseida Therapeutics' liquidity, profitability, solvency, and operating efficiency, Poseida Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.

Poseida Therapeutics Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Poseida Therapeutics has an asset utilization ratio of 23.62 percent. This suggests that the Company is making $0.24 for each dollar of assets. An increasing asset utilization means that Poseida Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.

Poseida Therapeutics Ownership Allocation

Poseida Therapeutics owns a total of 97.47 Million outstanding shares. Over half of Poseida Therapeutics' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.

Poseida Therapeutics Profitability Analysis

The company reported the previous year's revenue of 64.7 M. Net Loss for the year was (123.43 M) with loss before overhead, payroll, taxes, and interest of (21.57 M).

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Stocks Directory module to find actively traded stocks across global markets.

If you are still planning to invest in Poseida Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Poseida Therapeutics' history and understand the potential risks before investing.